DM
RIGL icon

Deerfield Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Deerfield Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-233,137
Closed -$5.2M – 103
2016
Q2 		$5.2M Sell
233,137
-6,649
-3% -$165K 0.2% 72
2016
Q1 		$4.99M Hold
239,786
– – 0.21% 70
2015
Q4 		$7.27M Hold
239,786
– – 0.29% 70
2015
Q3 		$5.92M Hold
239,786
– – 0.23% 84
2015
Q2 		$7.7M Hold
239,786
– – 0.26% 82
2015
Q1 		$8.56M Hold
239,786
– – 0.28% 68
2014
Q4 		$5.44M Hold
239,786
– – 0.2% 77
2014
Q3 		$4.65M Hold
239,786
– – 0.17% 94
2014
Q2 		$8.7M Buy
239,786
+137,042
+133% +$4.66M 0.35% 71
2014
Q1 		$3.99M Buy
102,744
+26,376
+35% +$940K 0.16% 96
2013
Q4 		$2.18M Sell
76,368
-30,405
-28% -$892K 0.11% 89
2013
Q3 		$3.82M Sell
106,773
-164,232
-61% -$5.99M 0.18% 86
2013
Q2 		$9.05M Buy
+271,005
New +$12.3M 0.43% 64

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deerfield Management's RIGL Position: Q3 2016 in Review

Deerfield Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2016, closing a stake of 233,137 shares — an estimated $5.2M sold.

Deerfield Management first reported a position in RIGL in Q2 2013 and held it in 13 quarters. The position peaked at $9.05M in Q2 2013. 121 funds tracked by Wall St. Rank hold RIGL as of Q3 2016.

  • Deerfield Management reported no remaining Rigel Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Deerfield Management sold 233,137 Rigel Pharmaceuticals shares in Q3 2016, an estimated $5.2M.
  • Deerfield Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Deerfield Management's Rigel Pharmaceuticals position peaked at $9.05M in Q2 2013.
  • 121 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2016.

Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.